Skip to main content
. 2022 Nov 15;17(11):e0277706. doi: 10.1371/journal.pone.0277706

Fig 1. Change in NITs of liver steatosis and fibrosis from baseline.

Fig 1

Value at baseline for A: Median LFS of 0.60 for placebo and 0.63 for aleglitazar, B: Mean LAP of 69.5 for placebo and 67.8 for aleglitazar, C: Mean FIB-4 of 1.40 for placebo and 1.44 for aleglitazar, D: Mean NFS of -0.50 for placebo and -0.41 for aleglitazar. Error bars indicate 95% CIs. Change from baseline is significantly different in the aleglitazar and the placebo group at all timepoints ≥3 mohs for all proxies (all P<0.001).